What is the optimal peri‑operative anticoagulation and antiplatelet management for a patient undergoing triple coronary artery bypass grafting (CABG) with an atrial appendage clip?

Optimal Perioperative Anticoagulation and Antiplatelet Management for Triple CABG with Atrial Clip

For a patient undergoing triple CABG with an atrial appendage clip, initiate aspirin 100-325 mg within 6 hours postoperatively and continue indefinitely; if the patient has atrial fibrillation requiring anticoagulation (the likely indication for the atrial clip), start a DOAC (preferred over warfarin) and continue aspirin <100 mg daily for up to 1 year post-CABG, then transition to DOAC monotherapy.

Preoperative Management

Antiplatelet Therapy Discontinuation

If the patient is on dual antiplatelet therapy (DAPT) preoperatively:

• Clopidogrel and ticagrelor: Discontinue 5 days before surgery 1, 2
• Prasugrel: Discontinue 7 days before surgery 1, 2
• Aspirin: Continue throughout the perioperative period 2, 3

The evidence strongly supports continuing aspirin preoperatively (100-325 mg daily) as it reduces perioperative cardiovascular events without significantly increasing bleeding risk 2, 4. The ATACAS trial with over 2,100 CABG patients demonstrated that preoperative aspirin neither increased bleeding complications nor reoperation rates 5.

Critical Timing Consideration

If urgent/emergency surgery is required and P2Y12 inhibitors cannot be stopped for the recommended duration: Discontinue for at least 24 hours to reduce major bleeding complications 2. However, be aware that ticagrelor cessation <48 hours before CABG significantly increases bleeding risk (HR: 4.77) 6.

Postoperative Antiplatelet Management

Immediate Postoperative Period (First 6 Hours)

Initiate aspirin 100-325 mg within 6 hours postoperatively unless there are active bleeding concerns 2, 4. This timing is critical for preventing early graft occlusion and reducing adverse cardiovascular events 2.

Standard CABG Without AF (No Atrial Clip Scenario)

If this were standard CABG without atrial fibrillation:

• Continue aspirin indefinitely 2, 4
• Consider DAPT (aspirin + clopidogrel) for 12 months if the patient had ACS 1
• Restart DAPT at maintenance dose within 48-72 hours after surgery when deemed safe by the cardiac surgical team 1

Anticoagulation Management for Atrial Clip Patients

Understanding the Atrial Clip Context

The atrial appendage clip indicates the patient has atrial fibrillation requiring stroke prevention. This fundamentally changes the antithrombotic strategy.

Optimal Anticoagulation Strategy

Start a DOAC (direct oral anticoagulant) postoperatively when bleeding risk is acceptable 7. DOACs are preferred over warfarin due to:

• More predictable pharmacokinetics
• Lower bleeding risk
• No need for INR monitoring
• Easier perioperative management 7

Combined Anticoagulation and Antiplatelet Therapy

For patients <1 year post-CABG with AF requiring anticoagulation:

• Continue aspirin (<100 mg daily) + DOAC for up to 1 year post-CABG 7
• After 1 year: Stop aspirin and continue DOAC monotherapy 7

This recommendation is based on the 2021 ACC Expert Consensus which specifically addresses post-CABG patients with AF: "We recommend continuing aspirin (<100 mg/day) if <1 year post-CABG surgery and stopping aspirin >1 year post-CABG surgery" 7.

If Patient Had Recent ACS

If the patient underwent CABG for acute coronary syndrome:

<12 months post-ACS:

• Stop aspirin
• Continue clopidogrel (preferred P2Y12 inhibitor with anticoagulation)
• Start DOAC
• This "triple therapy" should be as brief as possible 7

>12 months post-ACS:

• DOAC monotherapy is appropriate 7

Bleeding Risk Mitigation

DOAC Dose Adjustment

When combining DOAC with antiplatelet therapy, consider reduced-dose DOAC if bleeding risk is high 8:

• Rivaroxaban: 15 mg daily (instead of 20 mg) during concomitant antiplatelet therapy 8
• Dabigatran: 110 mg twice daily (instead of 150 mg) during concomitant antiplatelet therapy 8

Avoid High-Risk Combinations

• Do NOT use ticagrelor or prasugrel as part of triple therapy with aspirin and anticoagulation 8
• Clopidogrel is the preferred P2Y12 inhibitor when combining with anticoagulation 7

Gastrointestinal Protection

Initiate a proton pump inhibitor for the duration of combined antithrombotic therapy to reduce gastrointestinal bleeding risk 8.

Common Pitfalls to Avoid

1. Delaying aspirin restart beyond 48 hours postoperatively: This eliminates the graft patency benefit 4

2. Using warfarin instead of DOAC: Warfarin requires bridging, has unpredictable pharmacokinetics, and increases bleeding risk when combined with antiplatelet therapy 7

3. Continuing triple therapy beyond necessary duration: Bleeding risk accumulates over time without proportional ischemic benefit 7, 8

4. Stopping anticoagulation entirely: The atrial clip reduces but does not eliminate stroke risk in AF patients; anticoagulation is still typically indicated based on CHA2DS2-VASc score 7

5. Using full-dose DOAC with dual antiplatelet therapy: This significantly increases bleeding risk without proven benefit 8

Monitoring and Reassessment

• Assess bleeding risk regularly using validated scores (HAS-BLED, ARC-HBR) 7
• Reassess need for antiplatelet therapy at 1 year post-CABG 7
• Target INR 2.0-3.0 if warfarin must be used, with time in therapeutic range >70% 8
• Monitor for thrombocytopenia post-CABG, which may delay antiplatelet resumption (typically occurs with on-pump surgery) 5

Special Considerations for Off-Pump CABG

If off-pump CABG was performed, DAPT (aspirin + ticagrelor) may provide additional MACE reduction (OR: 0.42) 9, though bleeding risk remains elevated. This benefit-risk calculation should be individualized based on graft complexity and bleeding risk.